Loading clinical trials...

Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802) | Clinical Trials | Clareo Health

UNKNOWN

Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)

Serum Biomarkers Associated With Endothelial Dysfunction and Immune Inflammation for Portal Hypertension in Cirrhosis (Pan-CHESS1802)

NCT03713606•Nanfang Hospital, Southern Medical University

View on ClinicalTrials.gov

Summary

This is a prospective, multi-center diagnostic trial conducted at 6 liver centers in China designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and hepatic venous pressure gradient in cirrhosis.

Detailed Description

Hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal pressure, of which the measurement is invasive and therefore not suitable for routine clinical practice. The detection of serum biomarkers is potential for noninvasive diagnosis of portal hypertension in cirrhosis. However, many are still in the exploratory phases of testing and are not yet ready to enter clinical practice. This study prospectively enrolled participants in 6 liver centers (Beijing YouAn Hospital, Shandong Provincial Hospital, Beijing Shijitan Hospital, Beijing Friendship Hospital, Xingtai People's Hospital, and 302 Hospital of PLA) in China designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and HVPG in cirrhosis.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•age 18-75 years;
•confirmed cirrhosis based on histologic examination of liver or combined physical, laboratory, and radiologic findings, including a nodular surface, a coarse texture, and an enlarged caudate lobe of the liver.

Exclusion Criteria

•prior drug therapy (e.g. β-blocker, vasopressin) within two weeks
•prior surgeries (e.g. TIPS, partial splenic embolization/ devascularization, splenectomy, liver transplantation)
•non-sinusoidal portal hypertension \& HCC inability to adhere to study procedures
•pregnancy or unknown pregnancy status
•no informed consent

Locations (6)

302 Hospital of PLA

Beijing, China

Beijing Friendship Hospital

Beijing, China

Beijing Shijitan Hospital

Beijing, China

Beijing YouAn Hospital

Beijing, China

Shandong Provincial Hospital

Jinan, China

Xingtai People's Hospital

Xingtai, China

Key Dates

Start Date

September 30, 2018

Primary Completion Date

January 31, 2022

Completion Date

June 1, 2022

Last Updated

August 17, 2021

Enrollment

ESTIMATED participants

Conditions

Hypertension, Portal

Interventions

HVPG measurement

PROCEDURE

Contacts

Xiaolong Qi, M.D.

CONTACT

+86 18588602600 qixiaolong@vip.163.com

Yanna Liu

CONTACT

+86 15625076784 lauyenna@126.com

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05282121

Liver DiseasesHypertension, Portal

View study

TERMINATEDPHASE2

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05161481

Hypertension, Portal

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 17, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)

Inclusion Criteria

Exclusion Criteria

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis